tiprankstipranks
Trending News
More News >
Coya Therapeutics, Inc. (COYA)
NASDAQ:COYA
US Market

Coya Therapeutics, Inc. (COYA) Stock Forecast & Price Target

Compare
71 Followers
See the Price Targets and Ratings of:

COYA Analyst Ratings

Strong Buy
3Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Coya
Therapeutics, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

COYA Stock 12 Month Forecast

Average Price Target

$17.67
▲(213.85%Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Coya Therapeutics, Inc. in the last 3 months. The average price target is $17.67 with a high forecast of $20.00 and a low forecast of $15.00. The average price target represents a 213.85% change from the last price of $5.63.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","21":"$21","8.25":"$8.25","12.5":"$12.5","16.75":"$16.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,8.25,12.5,16.75,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.55,6.661538461538461,7.773076923076923,8.884615384615385,9.996153846153845,11.107692307692307,12.21923076923077,13.330769230769231,14.442307692307693,15.553846153846155,16.665384615384617,17.776923076923076,18.888461538461538,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.55,6.4823076923076925,7.414615384615384,8.346923076923076,9.27923076923077,10.211538461538462,11.143846153846155,12.076153846153847,13.008461538461539,13.94076923076923,14.873076923076923,15.805384615384614,16.73769230769231,{"y":17.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.55,6.276923076923077,7.003846153846154,7.73076923076923,8.457692307692307,9.184615384615384,9.911538461538461,10.638461538461538,11.365384615384615,12.092307692307692,12.819230769230769,13.546153846153846,14.273076923076921,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.19,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.95,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.8,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.62,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.03,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.68,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.04,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.35,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.08,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.31,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.28,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.55,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$20.00Average Price Target$17.67Lowest Price Target$15.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on COYA
Ram SelvarajuH.C. Wainwright
H.C. Wainwright
$18
Buy
219.72%
Upside
Reiterated
06/09/25
Coya Therapeutics: Strengthened Patent Estate and Upcoming Catalysts Support Buy Rating
Lucid Capital Analyst forecast on COYA
Elemer PirosLucid Capital
Lucid Capital
$20
Buy
255.24%
Upside
Initiated
06/09/25
Coya Therapeutics initiated with a Buy at Lucid CapitalCoya Therapeutics initiated with a Buy at Lucid Capital
BTIG
$15
Buy
166.43%
Upside
Reiterated
05/13/25
BTIG reiterates Buy Rating on Coya Therapeutics (COYA)BTIG analyst Thomas Schrader reiterated a Buy rating and $15.00 price target on Coya Therapeutics (NASDAQ: COYA)
D. Boral Capital Analyst forecast on COYA
Jason KolbertD. Boral Capital
D. Boral Capital
$15
Buy
166.43%
Upside
Initiated
12/04/24
Coya Therapeutics initiated with a Buy at D. Boral CapitalCoya Therapeutics initiated with a Buy at D. Boral Capital
Chardan Capital Analyst forecast on COYA
Keay NakaeChardan Capital
Chardan Capital
$14
Buy
148.67%
Upside
Reiterated
10/30/24
Promising Phase II Trial Results Support Buy Rating for Coya Therapeutics' Alzheimer's Treatment
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on COYA
Ram SelvarajuH.C. Wainwright
H.C. Wainwright
$18
Buy
219.72%
Upside
Reiterated
06/09/25
Coya Therapeutics: Strengthened Patent Estate and Upcoming Catalysts Support Buy Rating
Lucid Capital Analyst forecast on COYA
Elemer PirosLucid Capital
Lucid Capital
$20
Buy
255.24%
Upside
Initiated
06/09/25
Coya Therapeutics initiated with a Buy at Lucid CapitalCoya Therapeutics initiated with a Buy at Lucid Capital
BTIG
$15
Buy
166.43%
Upside
Reiterated
05/13/25
BTIG reiterates Buy Rating on Coya Therapeutics (COYA)BTIG analyst Thomas Schrader reiterated a Buy rating and $15.00 price target on Coya Therapeutics (NASDAQ: COYA)
D. Boral Capital Analyst forecast on COYA
Jason KolbertD. Boral Capital
D. Boral Capital
$15
Buy
166.43%
Upside
Initiated
12/04/24
Coya Therapeutics initiated with a Buy at D. Boral CapitalCoya Therapeutics initiated with a Buy at D. Boral Capital
Chardan Capital Analyst forecast on COYA
Keay NakaeChardan Capital
Chardan Capital
$14
Buy
148.67%
Upside
Reiterated
10/30/24
Promising Phase II Trial Results Support Buy Rating for Coya Therapeutics' Alzheimer's Treatment
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Coya Therapeutics, Inc.

1 Month
xxx
Success Rate
6/14 ratings generated profit
43%
Average Return
+4.96%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of +4.96% per trade.
3 Months
xxx
Success Rate
10/14 ratings generated profit
71%
Average Return
+19.14%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +19.14% per trade.
1 Year
Keay NakaeChardan Capital
Success Rate
10/14 ratings generated profit
71%
Average Return
+37.21%
reiterated a buy rating 8 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +37.21% per trade.
2 Years
xxx
Success Rate
9/14 ratings generated profit
64%
Average Return
+15.30%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 64.29% of your transactions generating a profit, with an average return of +15.30% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

COYA Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
3
3
3
4
5
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
3
3
4
5
In the current month, COYA has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. COYA average Analyst price target in the past 3 months is 17.67.
Each month's total comprises the sum of three months' worth of ratings.

COYA Financial Forecast

COYA Earnings Forecast

Next quarter’s earnings estimate for COYA is -$0.41 with a range of -$0.52 to -$0.22. The previous quarter’s EPS was -$0.44. COYA beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 43.48% of the time in the same period. In the last calendar year COYA has Outperformed its overall industry.
Next quarter’s earnings estimate for COYA is -$0.41 with a range of -$0.52 to -$0.22. The previous quarter’s EPS was -$0.44. COYA beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 43.48% of the time in the same period. In the last calendar year COYA has Outperformed its overall industry.

COYA Sales Forecast

Next quarter’s sales forecast for COYA is $940.00K with a range of $0.00 to $4.20M. The previous quarter’s sales results were $257.88K. COYA beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 49.57% of the time in the same period. In the last calendar year COYA has Outperformed its overall industry.
Next quarter’s sales forecast for COYA is $940.00K with a range of $0.00 to $4.20M. The previous quarter’s sales results were $257.88K. COYA beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 49.57% of the time in the same period. In the last calendar year COYA has Outperformed its overall industry.

COYA Stock Forecast FAQ

What is COYA’s average 12-month price target, according to analysts?
Based on analyst ratings, Coya Therapeutics, Inc.’s 12-month average price target is 17.67.
    What is COYA’s upside potential, based on the analysts’ average price target?
    Coya Therapeutics, Inc. has 213.85% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is COYA a Buy, Sell or Hold?
          Coya Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Coya Therapeutics, Inc.’s price target?
            The average price target for Coya Therapeutics, Inc. is 17.67. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $20.00 ,the lowest forecast is $15.00. The average price target represents 213.85% Increase from the current price of $5.63.
              What do analysts say about Coya Therapeutics, Inc.?
              Coya Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of COYA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis